Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.67 +1.20%

+$0.15 today

Market cap
$336.08M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.18M

Average 0.09M

Income Statement

Follow revenue through to earnings.

Revenue

$36,000.00

FY 2025 · Annual

-41.0% YoY

Operating Income

-$203.77M

FY 2025 · Annual

Net Income

-$274.45M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

LYEL Earnings Waterfall · TTM

NASDAQ:LYEL · Revenue to Net Income

Key Ratios

EPS$-12.74
Gross Margin-29050.0%
Net Margin-1086389.2%
P/E Ratio-2.0
P/S Ratio85806.9

Analysis

$31.0K of revenue converted into -$246.4M of net income for the selected period. Gross margin is -29050.0% and net margin is -1086389.2%, showing how much revenue survives after costs and taxes. EPS is $-12.74, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-3S-3 filingNov 13, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026

How much revenue does LYEL generate?

Lyell Immunopharma, Inc. (LYEL) reported $36,000.00 of revenue in fiscal 2025.

Is LYEL profitable?

Lyell Immunopharma, Inc. (LYEL) reported -$274.45M of net income, with a net margin of -762355.6%.